LCB-2151

Overview

LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation ), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis . LCB-2151 can be used for radiation therapy of cancers research.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Carnitine Palmitoyltransferase (CPT) | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Oxidative Phosphorylation | Products > Signaling Pathways > Mitochondrial Metabolism

Product Information

• Catalog No.: HY-175673
• CAS No.: 2211175-99-2
• Molecular Formula: C37H43F8N3O5S2
• Molecular Weight: 825.87
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source